This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEAAP0BV_M.jpg
Operating profit was 150.5 billion yen ($1.11 billion) in the three months through June 30, the drugmaker said, compared with 249 billion yen a year earlier.
The company held its forecast for full-year operating profit at 520 billion yen. That compares with a consensus forecast of 539 billion yen, according to a Refinitiv poll of 15 analysts.
Takeda benefited from a one-time gain of 131.4 billion yen a year ago when it sold off the diabetes assets to refocus on core businesses following its acquisition of Shire Plc (LON:SHP).
($1=135.3400 yen)